EGFR and non-small cell lung carcinoma: The IPASS (Iressa Pan-Asia Study) [15] was regarded as the milestone for the clinical application of EGFR TKI, because it was the first randomized clinical trial to compare EGFR-TKI with chemotherapy at first-line treatment for advanced NSCLC with adenocarcinoma.